Yesterday we focused on the June Oppenheimer Report for Sevoflurane. Today we look at the August Oppenheimer Report. The crucial fact to take from this report is that Sevoflurane is on track and 2008 will represent an extremely strong year in its distribution as the Bethlehem, PA, plant approaches production capacity.
The August 18, 2007, Oppenheimer Report – continues to support the previous Oppenheimer Report of June 28.
In a nutshell this report and these graphs taken from the report indicate the growth expected by Minrad in the Sevoflurane market.
As you can see the annual projections show a strong, strong, strong upward trend in the worldwide Sevoflurane market for Minrad. And while RxElite has only the U.S. distribution rights, this indicates a powerful growth opportunity:
- 2007 – $20M
- 2008 – $57M
- 2009 – $81M
- 2010 – $92M
The Sevoflurane market in the U.S. is at conservative estimates $350M. In the June Oppenheimer Report RxElite delivered a forecast of 11%-15% yr-yr market growth: that is $38.5M to $52.5M in market growth for RxElite. Extrapolating that out over the Minrad Annual Chart leads to very strong growth conclusions.
Servoflurane
Investor Profile from Rx Elite
Source: RxElite Holdings, Inc.
RxElite Holdings, Inc.
Ph: (208) 288-5550
Toll Free: (800) 414-1901
Fax: (208) 288-1191 Investor Relations
Charlie Forshee, 215-885-4981
investorrelations@rxelite.com
Segue Ventures LLCAbout RxElite Holdings, Inc.: RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause the our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
Disclosure: Pentony Enterprises LLC was compensated $18,000.00. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC,9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com.